Turning early discovery into investable opportunity
The most promising science rarely fails for lack of ambition. It fails in the gap between the lab and the clinic, where breakthroughs must prove they can become fundable companies with pipeline and ultimately therapies that reach patients.
The 2nd Annual BioCentury Grand Rounds: Europe is built to close that gap. Over three days in Amsterdam, top VCs, academic innovators, biopharma R&D leaders and financial dealmakers come together to examine the latest advances in disease biology, therapeutic modalities and enabling technologies, and to answer the difficult question: what will it take to make this science investable?
Through curated sessions, candid debate and one-to-one partnering meetings, you'll discover cutting-edge research with genuine commercial potential, connect with the company-builders and early-stage investors who can accelerate translation, and uncover new opportunities to expand your portfolio and pipeline.
Get involved as a delegate, sponsor, or Presenting Company and take advantage of our timely registration rates:
Early Bird / Advanced Rate / Standard
- Industry Pass: €1,895 / €2,195 / €2,495
- Academic Pass + Poster Presentation: €415 / €520 / €625
- Presenting Company Presentation Package + Poster: €2,095 / €2,295 / €2,495
Entrepenuer or investor? Reach out to [email protected] to inquire about our special discounted rate.
Join us in Amsterdam, Sept. 23-25, 2026.
